Madrigal Pharmaceuticals Inc. (MDGL)

117.18 -4.01 (-3.309%)

IEX Real-Time Price

March 20, 2018 EST.

NASDAQ Capital Market : Healthcare

Prev Close 121.19

Price Open 120.88

Volume: 204,343

Avg Volume: 298,931

Market Cap: 1.67B

P/E Ratio -86.8

52 Wk Range 13.0886-154.75

MDGL Earning Report

Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

Q4 2017
-0.68 (2)

Q4 2017
-0.68 (2)

Q3 2017
-0.84 (1)

Q4 2016
0.00 (0)


Specialty Research: What The Lucrative NASH Market Has In Store (2018-03-16 15:55 SeekingAlpha)

Go to five companies in an industry, ask each of them intelligent questions about the points of strength and weakness of the other four, and nine times out of ten a surprisingly detailed and accurate picture of all five will emerge. - The Father of Growth Investing (Philip Fisher) As of la…


Madrigal Pharmaceuticals (MDGL) Presents At 38th Annual Cowen and Company Healthcare Conference - Slideshow (2018-03-15 13:31 SeekingAlpha)

The following slide deck was published by Madrigal Pharmaceuticals, Inc. in conjunction with this Read more …


Viking Tumbles On Phase 2 Trial Delay, But Remains A Solid Buy (2018-03-08 00:39 SeekingAlpha)

Viking Therapeutics ( VKTX ) reported an update on its programs in after-hours trade on Wednesday. Most notably it noted that it would have to delay data for its phase 2 trial using its drug VK2809. While this piece of news is disappointing, it can't be argued that the company has anothe…


NASH Series 5 - Diagnosis: The Challenge And A Look At Madrigal (2018-02-22 08:00 SeekingAlpha)

In previous articles, we have noted the growing prevalence of NAFLD and NASH, which is being driven by growing prevalence of diabetes and obesity. Both diabetes and obesity have strong association with NAFLD. As we noted in the last article, in Western countries, NAFLD prevalence is seen at ar…


Madrigal Pharmaceuticals: Elucidating The Positive Outcomes Of The Phase 2 Trial For Familial Hypercholesterolemia (2018-02-11 07:41 SeekingAlpha)

There is more to learn from Texas Instruments and Central California Electronics situations. When I originally acquired these Texas Instrument shares in the summer of 1995, they were bought for the longest type of long-range investment. It seemed to me the company fully warranted this degree …


Madrigal Pharmaceuticals: Buy The Dip (2018-02-10 07:07 SeekingAlpha)

Shares of Madrigal Pharmaceuticals ( MDGL ) have risen by around 35% since my mid-December article suggesting that readers "buy the secondary offering" in this intriguing revaluation and catalyst play. Figure 1: MDGL daily advanced chart (Source: Finviz Elite ) (Disclosure: Contains …



Shares Outstanding: 14.23M

Top 15 Institution Percent: 30.30

Price To Sales: N/A

Price To Book: 9.15

Revenue: N/A

Gross Profit: N/A

Cash: 169.43M

Debt: N/A

Return On Assets: -26.68

Return On Equity: -28.49

Profit Margin: N/A

Price History

Beta: 1.41

50-day Moving Avg: 127.07

200-day Moving Avg: 58.96

YTD Change: 20.28

5-day Change: -1.96

1-month Change: -13.81

3-month Change: 23.80

6-month Change: N/A

1-year Change: N/A

Revenue Per Share: 0.00

Revenue Per Employee: 0.00


Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -

Company Profile

Name: Madrigal Pharmaceuticals Inc.

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Sector: Healthcare


Madrigal Pharmaceuticals Inc is a company focused on the development of novel compounds for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH).